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Summary-The development of an in vitro bioassay of high specificity, sensitivity and precision for 
the measurement of low circulating concentrations of biologically active glycoprotein hormones has 
offered exciting new insights into the in uivo secretion and metabolic clearance of luteinizing hormone 
(LH) in various pathophysiolo~cal states. Moreover, the most recent combined application of the 
rat interstitial cell testosterone (RICT) bioassay and a novel multiple-parameter deonvolution model 
has allowed investigators to dissect plasma concentration profiles of bioactive LH into defined 
secretory bursts, which have numerically explicit amplitudes, locations in time, and durations, and 
are acted upon by dete~inable subject- and study-specific endogenous metabolic clearance r&es. 
Here, we have: (i) reviewed the ability of the endogenous GnRH pulse signal to regulate the in uivo 
secretion of biologically active LH molecules as assessed in the RICT and by deconvolution 
mechanics; (ii) demonstrated that low-dose exogenous GnRH pulses effectively mimic spontaneous 
bioactive LH pulsa6lity; (iii) investigated the role of endogenous androgen and estrogen in 
modulating bioactive gonadotropin secretion in men and women; and (iv) described significant 
alterations in endogenous LH bioactivity in puberty and healthy aging. 
INTRODUffION 
With the advent of radioimmunoassays more than a 
decade ago, the properties of immunoactive glyco- 
protein hormone secretion and metabolic clearance 
have been characterized under various pathophysio- 
logical conditions [l]. However, the development of 
a valid in vitro assay system for the quantitation of 
bidlogically active LH in plasma (the rat interstitial 
cell testosterone bioassay, RICT) revealed a range of 
discrepancies between immunoactive estimates and 
bioactivity in various pathological and physiological 
states (21. In particular, studies of bioactive LH 
release in healthy young men, in young women of 
reproductive age evaluated throughout the normal 
menstrual cycle, and in postmenopausal women dis- 
closed that significant discordance existed between 
immunoactive and bioactive LH pulsations, such 
that 14-30% of bioactive LH pulses were unaccom- 
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panied by significant immunoactive LH pulses [2-4]. 
Moreover, serum bioactive LH concentrations in 
spontaneous gonadotropin pulses increased prefer- 
entially over immunoactive LH concentrations, re- 
sulting in a significantly enhanced bio:immuno LH 
ratio, which could be mimicked by the exogenous 
administration of low-dose pulsed GnRH but not by 
continuous GnRH infusion and/or pharmacological 
GnRH injections [S-7]. In addition to pulsatile bio- 
active LH release in individual subjects, mean serum 
bioactive LH concentrations could be shown to vary 
strikingly in puberty, during the normal menstrual 
cycle, with healthy aging, and in response to manipu- 
lations of the sex-steroid hormone milieu [l-5,8,9]. 
Moreover, in each of these circumstances, the RICT- 
determined bioactivity of LH can confer substantial 
additional info~ation regarding physiological regu- 
lation and pathological alterations in LH secretion 
and/or clearance. Thus, the measurement of bioactive 
LH can be viewed as a clinical and experimental 
probe of the gonadal axis that offers distinct and 
complementary insights into hypothalamo-pituitary 
function in health and disease. Here, we have pre- 
sented a systematic examination of the physiological 
and pathological regulation of bioactive LH secretion 
and clearance under selected clinical conditions of 
health and disease. 
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Fig. 1. Pulsatile bioactive and immunoactive LH release and 
resultant bio:immuno LH ratios obtained during three 
stages of the menstrual cycle in three normal women. Serial 
blood samples were collected at 10 or 15 min intervals 
for 36&480 min (horizontal axis) in the early follicular, 
late follicular (midcycle), and luteal phases. (Adapted with 
permission from Ref. 141.) 
1. IMPACT OF THE GNRH SIGNAL ON 
BIOACTWE LH SECRETION 
(a) Role of the endogenous GnRH pulse signal in 
regulating bioactive LH release in man: Pulsatile 
nature of bioactive LH release 
Initial studies of healthy young men and post- 
menopausal women during estrogen deprivation re- 
vealed a distinctly pulsatile mode of bioactive LH 
release in vivo [3]. In these early studies, bioactive LH 
pulses were detected at a median periodicity of 
approximately every 76 min in young men and every 
90 min in estrogen-unreplaced postmenopausal indi- 
viduals. Moreover, mean (*SD) serum bioactive 
LH concentrations were 41 f lSmIU/ml in young 
men and 450 + 24 mIU/ml in postmenopausal 
women, with corresponding bio : immuno LH ratios 
of 4.0 + 1.0 (men) and 5.4 f 1.3 (postmenopausal 
women). The incremental amplitudes of bioactive 
LH pulsations were 19 f 5.5 mIU/ml in young men 
and 153 & 107 mIU/ml in postmenopausal women 
(P < 0.01). In addition, statistical analyses revealed 
that bio: immuno LH ratios within LH pulses signifi- 
cantly exceeded those in the inter-peak “valleys” 
[2, 31. Collectively, these observations indicated that 
bioactive LH release occurs in distinct and episodic 
pulsations, which are associated with an increase in 
circulating concentrations of LH enriched in biologi- 
cal activity. As discussed further below, the high 
bioactivity of spontaneous LH pulsations could result 
from the preferential secretion of LH molecules of 
high bioactivity when the pituitary gland is stimu- 
lated by quanta of endogenous GnRH, and/or differ- 
ential clearance of bioactive and immunoactive 
hormone with or without interconversion of various 
molecular species of circulating LH. 
In addition to the striking amplitude differences 
in pulsatile LH release between young men and 
postmenopausal women (vide supra), young women 
of reproductive age exhibited both frequency and 
amplitude modulation of pulsatile bioactive LH re- 
lease throughout the menstrual cycle [4]. This pattern 
is illustrated in Fig. 1. Mean bioactive LH concen- 
trations (+ SD) in repetitively sampled young women 
varied from 23 + 15 mIU/ml in the early follicular 
phase to 43 f 18 mIU/ml in the late follicular phase 
and 27 f 23 mIU/ml in the luteal phase of the 
menstrual cycle [4]. These changes in mean serum 
bioactive LH concentrations were accompanied by 
significant alterations in bioactive LH pulse fre- 
quency. In particular, bioactive LH pulse frequency 
increased from 0.47 + 0.23 pulses/h in the early fol- 
licular phase to 1 .O f 0.12 pulses/h in the late follicu- 
lar phase, and then decreased to 0.34 f 0.05 pulses/h 
in the mid-luteal phase. The maximal amplitude of 
LH peaks was also modulated throughout the men- 
strual cycle, with respective values of 3 1 + 18 mIU/ml 
(early follicular phase), 59 + 27 mIU/ml (late follicu- 
lar phase), and 43 + 26 mIU/ml (mid-luteal phase). 
Thus, we can conclude that bioactive LH release 
occurs in distinct pulsations in healthy young women, 
and that this pulsatile mode of bioactive gonado- 
tropin secretion exhibits both amplitude and fre- 
quency modulation throughout the normal menstrual 
cycle [4]. 
Since experimental studies in several animal species 
have demonstrated a close correspondence between 
LH pulsatility and episodic GnRH release in hypo- 
thalamo-pituitary-portal blood [lo, 111, we can infer 
that the pulsatile release of bioactive LH in normal 
men, postmenopausal women, and young women 
studied throughout the menstrual cycle reflects 
episodic endogenous GnRH action. Moreover, al- 
though variations in bioactive LH pulse amplitude 
can result from changes in either the amplitude of the 
endogenous GnRH pulse signal and/or changes in 
pituitary gonadotrope-cell responsiveness, significant 
alterations in bioactive LH pulse frequency can be 
taken to reflect corresponding modulation of the 
hypothalamic GnRH pulse generator [l]. Thus, the 
Pulsatile bioactive LH secretion 741 
Endogenoua LH Peak 
impact of GnRH pulse frequency on the release of 







200 lmmunoactive 40 
1 
Immunoactlve 
OJ . * 
4, 
.g 4 a 
Y m 3 
I. pLMEN 
..* + t *a,.* . . . . 
2 < 
I 1) _-“-_:_..~ 
0 100 200 300 -40 -20 0 20 40 60 
Time (min) Time (min) 
Fig. 2. Panel A. Profiles of mean (+ SEM) plasma bioactive (upper subpanel) and immunoactive (middle 
subpanel) LH concentrations and median B:I ratios (lower subpanel) in 7 normal men before and after 
exogenous low-dose (10 mcg) pulsed GnRH injection, The arrow designates the time of injection of the 
exogenous GnRH pulse. Panel B. Similar data from 23 endogenous LH peaks from 7 men synchronized 
in relation to their maximal intrapulse value (given as time 0). (Adapted with permission from Ref. [5].) 
bioactive LH can be investigated under clinical or 
pathological conditions in which LH pulse frequency 
is accelerated experimentally or occurs at various 
frequencies physiologically. The latter circumstance 
prevails during the normal human and primate men- 
strual cycles, when spontanteous bioactive LH pulse 
frequency exhibits significant variation, such that 
increased LH pulse frequency occurs in the late 
follicular phase associated with enhanced circulating 
concentrations of estradiol and bioactive gonado- 
tropin hormone [4, 121. 
Experimental acceleration of the GnRH pulse 
generator can be accomplished by pharmacological 
blockade of the endogenous mu-opiate receptor sys- 
tem [13]. Administration of the long-acting selective 
mu opiate-receptor antagonist, naltrexone, sig- 
nificantly increased spontaneous bioactive LH 
pulse frequency, with a resultant enhancement in 
mean serum bioactive LH concentrations from 
26 f 11 mIU/ml to 33 f 12 mIU/ml in healthy young 
men [14]. In addition, maximal bioactive LH 
peak amplitudes increased from 39 k 13 to 
44 f 14 mIU/ml, as the bioactive LH interpulse 
interval declined from 200 _+ 19 min to 124 f 37 min 
(P < 0.002). This paradigm, in which the endogenous 
GnRH pulse signal frequency is selectively amplified, 
demonstrates that frequency modulation of GnRH’s 
stimulation of the pituitary gland offers one major 
mechanism for regulating the amount of biologically 
active LH secreted in viva. 
The trophic role of endogenous GnRH pulses on 
bioactive LH release in man is further supported by 
the prompt and major suppression of serum bioactive 
LH concentrations induced by injection of a potent 
and long-acting selective decapeptide antagonist of 
GnRH action [15]. Further studies utilizing a more 
potent GnRH antagonist revealed that serum bio- 
active LH concentrations declined to a greater degree 
than immunoactive LH concentrations, which re- 
sulted in a gradual fall in the serum bio:immuno LH 
ratio [16]. The latter observation could reflect a 
preferential decrease in the release of bioactive over 
immunoactive hormone, altered interconversion be- 
tween released bioactive and immunoreactive LH, 
and/or differences in the metabolic clearance rates of 
bioactive and immunoactive gonadotropin. There- 
after, “escape” occurred, with the reappearance of 
low-amplitude bioactive LH pulsations and stabiliz- 
ation of the serum bioactive LH concentration at a 
new but reduced level. 
The role of GnRH in controlling the secretion 
of biologically active LH molecules in uiuo can be 
examined further by injections of synthetically pure 
GnRH. Earlier investigations employing continuous 
infusions and/or pharmacologically large doses of 
GnRH failed to reveal any preferential release of 
bioactive over immunoactive LH in men or women, 
except during the late follicular phase of the 
menstrual cycle [6, 71. However, more recent studies 
utilizing low-dose (10mcg rather than 100mcg) 
intravenous pulses of GnRH have demonstrated 
a quantitatively greater increase in bioactive than 
immunoactive LH concentrations with a transient 
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Fig. 3. Panel A. Model of multiple-parameter convolution integral, in which circulating hormone 
concentrations are controlled by discrete secretory bursts which are acted upon by endogenous metabolic 
clearance rates [discussed fully in Ref. 171. Panels B and C. Illustrative profiles of spontaneous bioactive 
LH release with deconvolution-resolved secretory bursts in 2 healthy men. For each individual, the upper 
subpanel depicts serial serum bioactive LH concentrations measured by RICT in blood sampled at IO-mm 
intervals for 6 h. The continuous curve through the data represents the calculated reconvolution fit derived 
from simultaneous non-linear, multiple parameter estimation (see [17]). The lower panel gives the 
underlying significant individually resolved secretory bursts, as a plot of secretion rate versus time. Note 
that the resolved secretory pattern consists of punctuated burst-like episodes of bioactive hormone release 
without any jntervening “tonic” secretion. (Adapted with permission from Reference [19].) 
increase in the bio: immuno ratio: Fig. 2. This pattern 
closely recapitulated that recognized in spontaneous 
LH pulsations: Fig. 2B. Such results suggest that 
physiological GnRH pulse signals elicit the episodic 
secretion of LH molecules of high biological activity. 
The preferential increase in serum bioactive LH 
concentrations during spontaneous LH pulsations or 
in response to exogenous low-dose pulsed injections 
of GnRH could result from increased LH secretion 
andfor decreased clearance [ 171. Using deconvolution 
modeling, it is possible to resolve the amplitude, 
temporal location, and duration of individual under- 
lying LH secretory bursts and simultaneously esti- 
mate the half-time of endogenous LH disappearance 
from plasma [17, 181, as schematized in Fig. 3A. 
Accordingly, this new model of combined secretion 
and clearance was applied to spontaneous bioactive 
LH pulse profiles. In particular, as shown in Fig. 3B, 
episodic fluctuations in serum bioactive LH con- 
centrations could be accounted for by underlying 
secretory bursts of quantitatively defined amplitude, 
temporal location, and duration. The resolved 
secretory bursts of bioactive LH manifested an aver- 
age amplitude (maximal rate of secretion achieved 
within any given release episode) of 2.1 + 0.26 mIU/ 
ml/min [lP]. Thefrequency of bioactive LH secretory 
bursts was 6.5 +_ 0.25 pulses/6 h, which corresponded 
to a mean interpulse interval of 56 * 1.3 min [19]. 
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Table I. Exogenous GnRH-stimulated LH release in young men 
assessed by deconvolution analysis 
Maximal secretory rate 
(mIU/ml/min) 
Mass of LH released per 
burst (mIU/ml) 
Half-time of endogenous 
LH disappearance (min) 
l P < 0.01 vs bioactive LH. 
Bioacative LH 
6.5 2 0.9 
215 * 30 
49 + 5 
RIA LH 
2.2 i_ 0.708 
21 k 8.7. 
114+_ 12’ 
Data in Fig. 4 were subjected to multiple-parameter deconvolution 
analysis to resolve underlying LH secrerory rates and half-times 
of endogenous LH disappearance simultaneously [l7]. Secretory 
rates and mass are expressed per unit distribution volume, 
which is similar for bioactive and imm~noactiv~ LH [20]. The 
deconvoiution model assumes that concentration peaks result 
from secretory bursts of finite and determinable amplitudes, 
durations and temporal locations, which are acted upon by 
endogenous clearance kinetics. The individual secretory and 
clearance values of interest are determined by non-linear least 
squares parameter estimation after solution of the retevant 
convolution integral (schematized in Fig. 3A, see Ref [lfl). 
Moreover, computer-resolved LH secretory bursts 
had a mean half-duration (duration at half-maximal 
amplitude) of 12 It 1.5 min, which is remarkably 
shorter than the serum bioactive LH concentration 
peak of 56 5 5.5 min (P < 0.01). The simultaneously 
calculated half-time of endogenous bioactive LH 
disappearance in normal men was 53 k 5.4 min, 
which conforms closely to the independently deter- 
mined half-time of exogenous LH disappearance of 
65 + 4.9 min in hypopituitary men infused with 
highly purified human pituitary LH (NIH I-2) [20]. 
Thus, d~onvolution modeling of serum bioactive LH 
concentration series demonstrates not only that bio- 
logically active gonadotropin is secreted in short- 
lived, distinct and frequent bursts, but also that 
reasonable estimates of e~~Qge~o~~ bioactive LH 
half-lives can be accomplished without the injection 
of radiolabeled or unlabeled gonadotropin [19]. 
To assess whether the preferential increase in 
serum bioactive LH concentrations following pulsed 
GnRH injection results from increased secrerion, we 
applied deconvolution analysis to the bioactive and 
immunoactive LH pulses elicited by two consecutive 
low-dose (10 mcg) GnRH bolus infusions in a normal 
man. As shown in Fig. 4, and summarized numeri- 
cally in Table 1, the calculated underlying secretory 
bursts of bioactive LII exhibited significantly greater 
amplitudes (maximal rate of secretion) and were 
associated with a significantly larger mass of hor- 
mone released per secretory burst (area under the 
secretory impulse) than immunoactive hormone. The 
calculated half-lives of endogenous bioactive and 
immunoactive LH clearance in this example were 
49 + 5 min and 114 It 12 min. Thus, deconvolution 
analysis combined with the RICT bioassay permits US 




Half-life 114 min 
iII_I 
SD 5 min 
0 100 200 
Time (min) 
Fig. 4. Deconvolution analysis of serum bioactive (left panel) and immunoactive (right panel) LH 
concentrations after two consecutive two-hourly injections of low-dose pulsed GnRH (10 mcg) in a young 
normal man. The upper subpanels give the observed serial serum LH concentrations over time. The 
calculated reconvolution curve is shown through the observed data [17]. In the lower subpanels, the 
computer-resolved LH secretory bursts are depicted. The computer analysis assumes a multiple-parameter 
convolution integral, in which serum hormone concentrations are controlled by the number, amplitudes, 
durations, and temporal locations of all underlying secretory bursts, which are acted upon continuously 
by subject- and study-specific metabolic ciearanoe rates [17& Secretory and clearance (half-life) ammeter 
are calculated simultaneously from all data points and their intrasample variances considered jointly [ 171. 
The “SD” is the standard deviation of the resolved Gaussian secretory burst [Veldhuis J. D., Dufau M. L. 
and Johnson M. L., unpublished data]. 
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Fig. 5. Illustrative relationships between plasma bioactive 
and serum immunoactive LH concentrations in two of the 
Seven normal men who underwent blood sampling at 10 min 
intervals for 12 h. The line represents the best fit through 
the 2-dimensional elliptical variance spaces representing 
measurement errors inherent in both the bio- and immuno- 
assays. The y-intercepts for the regression lines for all 7 
normal men studied in this fashion were zero or slightly 
negative. Note break in axes near origin (Panel A) to 
accommodate the full range of LH values observed. 
(Adapted with permission from Ref. 5.) 
secreted at a more rapid rate and in larger amounts 
than immunoactive material. Moreover, bioactive 
LH is cleared more (rather than less) rapidly than its 
immunoactive counterpart in the same individual. 
We conclude that bioactive LH is released in 
episodic pulsations that exhibit both frequency and 
amplitude modulation under different pathophysio- 
logical conditions. In response to endogenous or 
exogenous pulses of GnRH, bioactive LH secretion 
occurs preferentially and in a burst-like mode. De- 
convolution analysis of LH concentrations measured 
in the RICT bioassay which is devoid of a nonspecific 
“blank” permits one to estimate the amplitudes, 
frequency, and duration of bioactive LH secretory 
bursts, and simultaneously calculate the half-time of 
endogenous bioactive LH disappearance in vivo. 
Altered serum bio:immuno LH ratios could alter- 
natively result if the RICT bioassay measured a 
certain “non-specific” or “blank” amount of bio- 
active LH. However, as shown in Fig. 5, the linear 
regressions of bioactive LH on immunoactive LH 
measured in serum samples collected at IO-min 
intervals for 12 h in normal men have y intercept 
values of 0 or less. Here, we used linear regression in 
which experimental uncertainty exists in both the 
dependent and independent variables (immunoactive 
and bioactive LH measurements) to estimate the 
two-dimensional error ellipses and the mean and 
statistical confidence limits for the regression co- 
efficients and intercept [5]. Accordingly, no “blank” 
bioactivity is demonstrable. Rather, positive x-axis 
intercepts indicated the occurrence of small quantities 
of nonspecific immunoactivity when bioactivity fell 
to 0 [5]. Moreover, we demonstrated that hypopitu- 
itary serum, although it contains small quantities of 
immunoactive LH, is devoid of measurable LH 
bioactivity in our RICT [5]. Thus, we can exclude the 
problems observed in certain other assays of a “non- 
specific” bioactivity. 
2. ROLE OF ENDOGENOUS ANDROGENS 
AND ESTROGENS IN REGULATING 
BIOACTIVE LH SECRETION 
(a) Role of estrogens 
TO probe the role of estrogens in regulating the 
secretion of bioactive LH, we have infused estradiol 
under steady-state conditions in healthy young men. 
The equilibrium infusion of estradiol at its daily 
endogenous production rate results in significant 
suppression of serum bioactive LH concentrations 
[21]: Fig. 6. Suppression of bioactive LH is more 
pronounced than that for immunoactive hormone, 
resulting in a decrease in the mean serum 
bio:immuno LH ratio. Conversely, when the non- 
steroidal, selective antiestrogen, tamoxifen hydro- 
chloride, is administered orally for 7 days, bioactive 
LH concentrations increase, and this increase is dis- 
proportionately large compared to the accompanying 
rise in immunoactive LH concentrations. The mech- 
anisms subserving this stimulatory effect of anti- 
estrogen in men include an acceleration of 
endogenous bioactive LH pulse frequency, which is 
associated with an increase in the maximal amplitude 
of LH concentration peaks but no major change in 
pituitary bioactive LH release in response to exo- 
genous pulses of GnRH [21]. Consequently, we infer 
that GnRH pulse frequency can modulate bioactive 
LH secretion and that inhibition of endogenous 
estrogen’s negative feedback action results in aug- 
mented bioactive LH release in the human. 
The clinical importance of estrogen’s negative feed- 
back effect on bioactive LH secretion was observed in 
a man with hyperestrogenemia associated with a 
benign, surgically resectable adrenal adenoma [22]. 
Prior to surgical removal of the tumor, the patient’s 
serum concentrations of bioactive LH and total and 
free testosterone were profoundly suppressed. After 
surgical cure, serum bioactive (and to a lesser degree, 





Fig. 6. Suppressive effects of steady-state estradiol infusion on mean serum LH concentrations in normal 
men. Seven normal men received 48 mcg of estradiol-17fi per day by continuous intravenous infusion for 
3: days. Mean serum concentrations of LH were determined by RICT bioassay (bio-LH) and immuno- 
assay (RIA-LH) under baseline (control) conditions and during the last 8 h of the estradiol infusion. Data 
represent mean + SEM (mIU/ml) serum LH concentrations obtained from blood withdrawn at 4 min 
intervals for 8 h. Corresponding changes in the serum LH bio:immuno ratio in response to steady-state 
estradiol infusion as shown in the right subpanel. The numerals in the control and estradiol-infusion 
columns denote individual men. (Adapted with permission from Ref. [21].) 
immunoactive) LH concentrations increased signifi- 
cantly into the normal range in association with a 
recovery of sexual function and restoration of plasma 
androgen concentrations. Thus, we can infer that 
in normal men endogenous estrogen operating at 
physiological concentrations restrains the secretion of 
bioactive LH and that pathological excess of estrogen 
significantly suppresses bioactive LH release with 
resultant clinical hypogonadism. 
Estrogen administration to postmenopausal 
women via an intravaginally-placed silastic ring im- 
pregnated with pure crystalline steroid provides an- 
other model in which to examine feedback actions of 
estrogen on the hypothalamo-pituitary axis [23]. We 
have observed that estrogen exerts a bipotential effect 
on LH release, with an acute suppression of LH pulse 
frequency and to a lesser degree LH pulse amplitude 
within 24 h, followed by a secondary increase in LH 
pulse frequency and amplitude on days S-10 of 
estrogen exposure. Thereafter, sustained suppression 
of LH concentrations occurs [23]. The secondary 
increases in serum LH concentrations observed on 
days S-10 of estrogen exposure in postmenopausal 
women reflect not only an increase in LH pulse 
frequency, but also an enhanced responsiveness to 
GnRH’s stimulation of LH release [24]. In particular, 
when two consecutive pulses of exogenous low-dose 
GnRH (10 mcg) are administered at 2-hourly inter- 
vals after five or ten days of estrogen exposure, the 
second pulse of GnRH elicits a significantly larger 
increase in LH concentrations than the first. This 
property of enhanced responsiveness to the serial 
doses of GnRH is referred to as GnRH self-priming. 
Accordingly, we infer that estrogen exerts time- 
dependent effects on the kinetics of GnRH’s self- 
priming action on the human pituitary gland. These 
results with RIA have been confirmed and extended 
recently by RICT bioassay. This self-priming action 
of GnRH on bioactive LH release is maximal after 5 
and 10 days of estrogen exposure, and can be demon- 
strated whether it is defined as an increase in the 
percentage amplitude of the second peak compared 
to the first, or as an incremental increase of the 
second peak maximum over the first (Veldhuis and 
Dufau, unpublished). Thus, we can infer that estro- 
gen in the human regulates the pituitary gland’s 
responsiveness to pulses of GnRH, such that en- 
hanced secretion of biologically active gonadotropin 
occurs during serial exposure to GnRH stimuli. 
Our finding of GnRH self-priming induced by 
estradiol is of particular importance to an under- 
standing of possible mechanisms subserving the 
generation of the pre-ovulatory LH surge. The pro- 
gressive increase in bioactive LH concentrations ob- 
served in the late follicular phase [4] that culminates 
in the preovulatory LH surge [12] could result from 
GnRH self-priming by a relevant strength-duration 
effect of endogenous estradiol on anterior pituitary 
gonadotrope function, i.e. on the synthesis, process- 
ing, and secretion of LH molecules enriched in bio- 
logical activity. Although this formulation does not 
necessitate concurrent increases in GnRH or LH 
pulse frequency during the preovulatory surge, poss- 
ible further acceleration of LH pulse frequency 
during the LH surge proper (as distinguished 
from during the late follicular phase, where bioactive 
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Fig. 7. Suppressive effect of equilibrium androgen (5-alpha- 
dihydrotestoserone) infusion on 8-h mean serum bioactive 
LH (“BIO”) and immunoactive (“RIA”) LH concentrations 
and the resulting bio:immuno LH ratio in normal men. 
Data are means f SEM (N = 7 subjects). [Veldhuis J. D. 
and Dufau M. L., unpublished observations.] 
LH pulse frequency does increase [4]) will require 
investigation. 
(6) Role of androgens 
To assess the ability of androgens to regulate 
bioactive LH secretion, we have infused the potent 
non-aromatizable androgen, 5-alpha-dihydrotestos- 
terone, at twice the production rate of testosterone in 
normal men [25]. This pharmacological maneuver 
significantly suppresses immunoactive LH pulse fre- 
quency, which can be restored to nearly normal when 
an opiate-receptor antagonist is co-administered 
with the androgen [25]. During dihydrotestosterone 
infusion, bioactive LH concentrations also decline 
significantly, as shown in Fig. 7. In fact, there is 
preferential suppression of serum bioactive over 
immunoactive LH concentrations in this circum- 
stance. Consequently, the mean bio:immuno LH 
ratio falls. The converse experiment, in which a 
selective nonsteroidal antiandrogen, flutamide hydro- 
chloride, is administered to young men to block 
endogenous androgen negative-feedback action has 
revealed an increase in plasma bioactive LH concen- 
trations with an accompanying rise the plasma 
bio:immuno LH ratio (Veldhuis and Dufau, un- 
published observations in four men). Although fur- 
ther detailed analyses are required to explore the 
mechanisms and nature of androgen’s regulation 
of bioactive LH secretion and/or clearance in the 
human, the preceding studies demonstrate that 
androgens can regulate circulating concentrations of 
bioactive gonadotropin in men. However, the exact 
extent to which such regulation occurs via frequency 
modulation of the GnRH pulse signal and/or by 
direct actions of androgen on gonadotrope cellular 
function has not been elucidated. In addition, further 
studies will need to focus on the explicit modulation 
by steroid hormones of distinct molecular isoforms 
of LH. 
In women, the role of endogenous androgens in 
regulating bioactive LH secretion has not been 
defined. However, we have recently observed several 
patients in whom androgen-secreting tumors of 
the adrenal gland or ovary were surgically curable. 
Under these conditions of excess endogenous andro- 
gen secretion, serum bioactive LH concentrations 
were profoundly suppressed in a postmenopausal 
individual, but relatively minimally suppressed in a 
premenopausal amenorrheic individual. After surgi- 
cal cure of the androgen-secreting tumor, bioactive 
LH concentrations returned to the castrate range in 
the postmenopausal patient, whereas they changed 
only slightly in the premenopausal woman despite a 
similarly profound fall in androgen levels. The mean 
serum bio : immuno LH ratio increased after andro- 
gen withdrawal in the postmenopausal patient, 
but did not change significantly after restoration of 
normal androgen concentrations in the pre- 
menopausal woman. Accordingly, further study will 
be required to dissect the nature and degree of 
regulation by endogenous androgen of bioactive LH 
secretion in women. 
3. ALTERATIONS IN BIOACTIVE LH RELEASE 
IN PUBERTY AND HEALTHY AGING 
(a) Puberty 
Prior to puberty, bioactive LH concentrations in 
girls are virtually undetectable [8]. During the early 
stages of puberty, as breast development is initiated 
(Tanner Stages 3 and 4), estrogen concentrations 
increase and serum bioactive LH concentrations also 
rise. There is a corresponding increase in the serum 
bio : immuno LH ratio [8]. However, even prior to the 
onset of increased endogenous estrogen secretion. 
some degree of pulsatility of bioactive LH release can 
be observed in healthy young girls, but frequent 
dissociation occurs between bioactive LH pulsatility 
and that of alpha subunit and/or immunoactive LH. 
Thus, the prepubertal context may be one in which 
bioactive LH measurements are particularly import- 
ant if the status of activation of the gonadal axis 
is difficult to determine clinically. Nonetheless, much 
further effort is required to delineate the properties of 
bioactive LH secretion and clearance throughout 
spontaneous normal pubertal stages and in various 
clinical conditions of arrested puberty, precocious 
puberty, or failure of pubertal activation. 
(b) Aging 
Although striking increases in serum bioactive LH 
concentrations occur in the postmenopausal setting, 
such castrate levels of gonadotropins are not ob- 
served in healthy aging men [2, 3,9]. Population 
studies of bioactive LH concentrations over a wide 
age-span indicate that a gradual decline in the 
bio:immuno-LH ratio can be observed 1261. This 
decline may reflect development of intercurrent illness 
and/or debility, as well as aging per se. Nonetheless, 
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Fig. 8. Bioactive LH concentration peaks and calculated underlying secretory episodes in reponse to two 
consecutive intravenous pulses of exogenous GnRH (10 mcg) in six young men and six older men. Plasma 
bioactive LH concentrations (upper panels, A and D) are given as means & SEM (N = 6 men), for which 
the accompanying mean calculated reconvolution curves are shown. Secretory episodes are plotted as 
mean regressions of secretory rates versus time (lower panels, B and C) which were estimated by 
multiple-parameter deconvolution [17]. Data in young and older men are presented in both the basal 
(control) and tamoxifen-treated state. Time zero denotes the time when the first of two consecutive 
intravenous injections of 10mcg exogenous GnRH was administered. (Adapted with permission from 
Reference [9].) 
healthy older men (ages greater than 65 and less than serum bio:immuno LH ratios [9]. Moreover, recent 
80) who are in robust, active, and exemplary health studies of bioactive LH pulsatility indicate that 12-h 
have serum bioactive LH concentrations similar to profiles of healthy aging men are quantitatively in- 
those of young men (ages 25-35) and exhibit similar distinguishable from those of normal young men [9]. 
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Fig. 9. Entire 24-h profile of pulsatile bioactive LH in a 
healthy older man (age 72). Blood was sampled at 10min 
intervals for 24 h and the resultant sera subjected to RICT 
(bioactive LH) and RIA. The corresponding LH time series 
and the serial bio:immuno LH ratios are shown (Urban 
R. J., Veldhuis J. D., Blizzard R. M. and Dufau M. L., 
unpublished data). 
On the other hand, provocative tests of the hypo- 
thalamepituitary-gonadal axis have revealed a clear 
diminution in bioactive LH secretory reserve with 
healthy aging. Thus, low-dose pulses of GnRH in 
healthy aging men elicit considerably less bioactive 
LH secretion, as assessed either by the plasma 
concentration profile or by deconvolution analysis: 
Fig. 8. Although the half-life of exogenously injected 
LH in older men is not known, deconvolution analy- 
sis has suggested that the half-life is not remarkably 
different from that in younger individuals [9]. Stimu- 
lation of the hypothalamo-pituitary-gonadal axis 
with the anti-estrogen, tamoxifen, also unmasked a 
deficit in bioactive LH secretory reserve in healthy 
aging men. The amplitude but not the frequency 
of bioactive LH pulses in tamoxifen-treated older 
men was significantly reduced compared to that in 
younger men. Thus, we can infer that healthy aging 
in men is associated with a decreased secretory 
reserve capacity of the gonadotrope for bioactive LH. 
Further studies are requited in aging individuals in 
order to elucidate the range of (patho-)physiological 
features present in healthy and/or debilitated popu- 
JELDIWB et al. 
lations. For example, by sampling blood at IO min 
intervals for 24 h, we have observed the entire nycto- 
hemeral profiles of bioactive LH release in healthy 
aging individuals. As shown in Fig. 9, during certain 
intervals throughout the day, serum bioactive 
LH concentrations fall almost to undetectable, as 
secretory burst activity is nearly completely arrested. 
Although 24 h data are of limited availability in 
younger men, the occurrence of such intervals of 
markedly decreased and/or polyphasic secretory 
burst activity in healthy older men raises the possi- 
bility of a defect in the neuroregulation of episodic 
LH release in this setting. 
4. SUMMARY 
Significant advances have been made in the last 
decade in our knowledge of the secretion and 
metabolic clearance of biologically active LH in vivo 
in the human. Evidence is presented that pulsatile or 
burst-like secretory episodes characterize bioactive 
LH release, and that the endogenous GnRH 
pulse signal exerts both amplitude and frequency- 
dependent control over bioactive LH secretion. En- 
richment in bioactivity is further modulated by sex 
steroid hormones and varies in puberty and healthy 
aging. Further studies will need to focus on the 
specific regulation of discrete molecular isoforms of 
LH in health and disease. 
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